rHuEPO — Competitive Intelligence Brief

rHuEPO (rHuEPO) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Erythropoiesis-stimulating agent (ESA). Area: Hematology.

marketed Erythropoiesis-stimulating agent (ESA) Erythropoietin receptor (EPOR) Hematology Small molecule

Target snapshot

rHuEPO (rHuEPO) — Amgen. rHuEPO (recombinant human erythropoietin) stimulates erythropoiesis by binding to the erythropoietin receptor on bone marrow progenitor cells to increase red blood cell production.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
rHuEPO TARGET	rHuEPO	Amgen	marketed	Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR)
Epogen	Epoetin Alfa-Epbx	Amgen	marketed	Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor	1989-01-01
continuation (darbepoetinum)	continuation (darbepoetinum)	Anemia Working Group Romania	marketed	Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR)
ARM A : IV iron + epoietin zeta	ARM A : IV iron + epoietin zeta	Centre Francois Baclesse	marketed	Iron supplement + Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR); iron as cofactor for hemoglobin synthesis
Erythropoietin carried on chitosan carrier	Erythropoietin carried on chitosan carrier	Ain Shams University	marketed	Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR)
Vifor and EPO	Vifor and EPO	Kunshan First People's Hospital Affiliated to Jiangsu University	marketed	Iron replacement agent and erythropoiesis-stimulating agent (ESA)	Iron (ferric ion) and erythropoietin receptor (EPOR)
ARM B: IV iron + epoietin zeta sequence	ARM B: IV iron + epoietin zeta sequence	Centre Francois Baclesse	marketed	Iron supplement + Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR); iron as cofactor for hemoglobin synthesis

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Erythropoiesis-stimulating agent (ESA) class)

1. Amgen · 4 drugs in this class
2. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 3 drugs in this class
3. Hospital de Clinicas de Porto Alegre · 2 drugs in this class
4. Pfizer · 2 drugs in this class
5. GlaxoSmithKline · 2 drugs in this class
6. Chong Kun Dang Pharmaceutical · 2 drugs in this class
7. Barts & The London NHS Trust · 1 drug in this class
8. Australian and New Zealand Intensive Care Research Centre · 1 drug in this class
9. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
10. Biocad · 1 drug in this class